# Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Source: https://onco.cc/trials/nct07085169/  
OnCo record `nct07085169` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Ruijin Hospital, now recruiting.

## Summary

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC is a phase 2, interventional study registered as NCT07085169 by Ruijin Hospital, with a registry enrolment figure of 50 participants, started 2025-08-01 and due to reach its primary completion in 2027-08-01. Interventions recorded: Trifluridine/tipiracil (TAS-102) plus bevacizumab. Conditions listed: Colo-rectal Cancer; Third-line and Beyond Therapy; TAS 102; Bevacizumab. Primary outcome: 6-month progression-free survival rate. Colorectal eligibility wording from the registry: "histologically confirmed adenocarcinoma of the colon or rectum". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07085169
- Phase: 2
- Setting: Low-dose Trifluridine/Tipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study
- Sponsor: Ruijin Hospital
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07085169: https://clinicaltrials.gov/study/NCT07085169

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07085169.json